Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience

Highlights ► The 32-year safety profile of M–M–R™II is described using data from postmarketing surveillance. ► Of ∼575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1 × 106 doses). ► This review provides evidence that the vaccine is safe and well-tolerated.

Saved in:
Bibliographic Details
Published in:Vaccine 2012-11, Vol.30 (48), p.6918-6926
Main Authors: Lievano, Fabio, Galea, Susan A, Thornton, Michele, Wiedmann, Richard T, Manoff, Susan B, Tran, Trung N, Amin, Manisha A, Seminack, Margaret M, Vagie, Kristen A, Dana, Adrian, Plotkin, Stanley A
Format: Article
Language:English
Subjects:
Age
Allergy and Immunology
Clinical trials
Data processing
Drug-Related Side Effects and Adverse Reactions - epidemiology
Historical account
Humans
live vaccines
Measles
Measles - epidemiology
Measles - prevention & control
Measles-Mumps-Rubella Vaccine - administration & dosage
Measles-Mumps-Rubella Vaccine - adverse effects
Measles-Mumps-Rubella Vaccine - immunology
monitoring
Morbidity
Mortality
Mumps
Mumps - epidemiology
Mumps - prevention & control
Product Surveillance, Postmarketing
Public health
Reviews
Rubella
Rubella - epidemiology
Rubella - prevention & control
Rubella virus
Safety
Vaccination
Vaccine
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► The 32-year safety profile of M–M–R™II is described using data from postmarketing surveillance. ► Of ∼575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1 × 106 doses). ► This review provides evidence that the vaccine is safe and well-tolerated.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.08.057